Logo

Agios Pharmaceuticals' Tibsovo (ivosidenib) Receives Approval For R/R Acute Myeloid Leukemia (AML) and IDH1 Mutation

Share this
Agios Pharmaceuticals' Tibsovo (ivosidenib) Receives Approval For R/R Acute Myeloid Leukemia (AML) and IDH1 Mutation

Agios Pharmaceuticals' Tibsovo (ivosidenib) Receives Approval For R/R Acute Myeloid Leukemia (AML) and IDH1 Mutation

Shots:

  • The approval is based on P-I AG120-C-011 (NCT02074839) study results assessing Tibsovo (ivosidenib- 500mg) in 174 patients with r/r AML and IDH1 mutation aged 67 yrs.
  •  P-I AG120-C-011 study results: CR+CRh rate 32.8%; CR rate 24.7%; median CR+CRh 8.2 mos.; median time to best response of CR or CRh 2.0mos.; median duration to exposure 3.9mos.; 41/110 (37.3%) patient became independent from RBC or platelet transfusion; 21/174 (12%) are on stem cell transplantation + Tibsovo treatment
  • Tibsovo (ivosidenib- 500mg) is a novel PO isocitrate dehydrogenase-1 (IDH1) inhibitor targeted for r/r AML with IDH1 mutation

Ref: Agios | Image: The Street

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions